See the latest news and media coverage for KDventures. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life science investment company
kd-ventures.comLast updated
In short: KDventures rebranded from Karolinska Development, reported a 35% H1 2026 NAV drop, and advanced key portfolio clinical trials.
The report shows a net loss of 485 million SEK and a net asset value per share of 0.89 SEK, driven by valuation reductions in the portfolio companies Umecrine Cognition and Dilafor.
The Phase 2a part enrolled 99 PBC patients with fatigue and cognitive symptoms; results due in H2 2026.
PharmNovo raised SEK 39 million for phase 2 study of PN6047, and KDventures wrote down its holding to SEK 5 million.
The phase 1b/2a study of drug candidate AC01 shows favorable safety and efficacy signals for heart failure patients.
KDventures AB ( ($SE:KDV.B) ) has shared an announcement. KDventures' portfolio company Umecrine Cognition has secured two Notices of Allowance from the U.S. Patent and...
KDventures (Q2 Update): NAV Falls 35% in H1, but Fundamentals Strengthen...
An announcement from KDventures AB ( ($SE:KDV.B) ) is now available.
KDventures’ portfolio company Umecrine Cognition has reported new data showing that more than half of primary biliary cholangitis patients suffer severe central fatigue and cognitive...
Track KDventures and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to KDventures and other trending companies.